Clinical testing of BRCA1 and BRCA2: A worldwide snapshot of technological practices

Amanda Ewart Toland, Andrea Forman, Fergus J Couch, Julie O. Culver, Diana M. Eccles, William D. Foulkes, Frans B.L. Hogervorst, Claude Houdayer, Ephrat Levy-Lahad, Alvaro N. Monteiro, Susan L. Neuhausen, Sharon E. Plon, Shyam K. Sharan, Amanda B. Spurdle, Csilla Szabo, Lawrence C. Brody

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Clinical testing of BRCA1 and BRCA2 began over 20 years ago. With the expiration and overturning of the BRCA patents, limitations on which laboratories could offer commercial testing were lifted. These legal changes occurred approximately the same time as the widespread adoption of massively parallel sequencing (MPS) technologies. Little is known about how these changes impacted laboratory practices for detecting genetic alterations in hereditary breast and ovarian cancer genes. Therefore, we sought to examine current laboratory genetic testing practices for BRCA1/BRCA2. We employed an online survey of 65 questions covering four areas: laboratory characteristics, details on technological methods, variant classification, and client-support information. Eight United States (US) laboratories and 78 non-US laboratories completed the survey. Most laboratories (93%; 80/86) used MPS platforms to identify variants. Laboratories differed widely on: (1) technologies used for large rearrangement detection; (2) criteria for minimum read depths; (3) non-coding regions sequenced; (4) variant classification criteria and approaches; (5) testing volume ranging from 2 to 2.5 × 105 tests annually; and (6) deposition of variants into public databases. These data may be useful for national and international agencies to set recommendations for quality standards for BRCA1/BRCA2 clinical testing. These standards could also be applied to testing of other disease genes.

Original languageEnglish (US)
Article number7
Journalnpj Genomic Medicine
Volume3
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

High-Throughput Nucleotide Sequencing
Technology
International Agencies
Patents
Neoplasm Genes
Genetic Testing
Ovarian Neoplasms
Databases
Breast Neoplasms
Genes
Surveys and Questionnaires

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Genetics(clinical)

Cite this

Toland, A. E., Forman, A., Couch, F. J., Culver, J. O., Eccles, D. M., Foulkes, W. D., ... Brody, L. C. (2018). Clinical testing of BRCA1 and BRCA2: A worldwide snapshot of technological practices. npj Genomic Medicine, 3(1), [7]. https://doi.org/10.1038/s41525-018-0046-7

Clinical testing of BRCA1 and BRCA2 : A worldwide snapshot of technological practices. / Toland, Amanda Ewart; Forman, Andrea; Couch, Fergus J; Culver, Julie O.; Eccles, Diana M.; Foulkes, William D.; Hogervorst, Frans B.L.; Houdayer, Claude; Levy-Lahad, Ephrat; Monteiro, Alvaro N.; Neuhausen, Susan L.; Plon, Sharon E.; Sharan, Shyam K.; Spurdle, Amanda B.; Szabo, Csilla; Brody, Lawrence C.

In: npj Genomic Medicine, Vol. 3, No. 1, 7, 01.12.2018.

Research output: Contribution to journalArticle

Toland, AE, Forman, A, Couch, FJ, Culver, JO, Eccles, DM, Foulkes, WD, Hogervorst, FBL, Houdayer, C, Levy-Lahad, E, Monteiro, AN, Neuhausen, SL, Plon, SE, Sharan, SK, Spurdle, AB, Szabo, C & Brody, LC 2018, 'Clinical testing of BRCA1 and BRCA2: A worldwide snapshot of technological practices', npj Genomic Medicine, vol. 3, no. 1, 7. https://doi.org/10.1038/s41525-018-0046-7
Toland, Amanda Ewart ; Forman, Andrea ; Couch, Fergus J ; Culver, Julie O. ; Eccles, Diana M. ; Foulkes, William D. ; Hogervorst, Frans B.L. ; Houdayer, Claude ; Levy-Lahad, Ephrat ; Monteiro, Alvaro N. ; Neuhausen, Susan L. ; Plon, Sharon E. ; Sharan, Shyam K. ; Spurdle, Amanda B. ; Szabo, Csilla ; Brody, Lawrence C. / Clinical testing of BRCA1 and BRCA2 : A worldwide snapshot of technological practices. In: npj Genomic Medicine. 2018 ; Vol. 3, No. 1.
@article{a68a42f2e01b441481ba62b8ac9e7afb,
title = "Clinical testing of BRCA1 and BRCA2: A worldwide snapshot of technological practices",
abstract = "Clinical testing of BRCA1 and BRCA2 began over 20 years ago. With the expiration and overturning of the BRCA patents, limitations on which laboratories could offer commercial testing were lifted. These legal changes occurred approximately the same time as the widespread adoption of massively parallel sequencing (MPS) technologies. Little is known about how these changes impacted laboratory practices for detecting genetic alterations in hereditary breast and ovarian cancer genes. Therefore, we sought to examine current laboratory genetic testing practices for BRCA1/BRCA2. We employed an online survey of 65 questions covering four areas: laboratory characteristics, details on technological methods, variant classification, and client-support information. Eight United States (US) laboratories and 78 non-US laboratories completed the survey. Most laboratories (93{\%}; 80/86) used MPS platforms to identify variants. Laboratories differed widely on: (1) technologies used for large rearrangement detection; (2) criteria for minimum read depths; (3) non-coding regions sequenced; (4) variant classification criteria and approaches; (5) testing volume ranging from 2 to 2.5 × 105 tests annually; and (6) deposition of variants into public databases. These data may be useful for national and international agencies to set recommendations for quality standards for BRCA1/BRCA2 clinical testing. These standards could also be applied to testing of other disease genes.",
author = "Toland, {Amanda Ewart} and Andrea Forman and Couch, {Fergus J} and Culver, {Julie O.} and Eccles, {Diana M.} and Foulkes, {William D.} and Hogervorst, {Frans B.L.} and Claude Houdayer and Ephrat Levy-Lahad and Monteiro, {Alvaro N.} and Neuhausen, {Susan L.} and Plon, {Sharon E.} and Sharan, {Shyam K.} and Spurdle, {Amanda B.} and Csilla Szabo and Brody, {Lawrence C.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41525-018-0046-7",
language = "English (US)",
volume = "3",
journal = "npj Genomic Medicine",
issn = "2056-7944",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Clinical testing of BRCA1 and BRCA2

T2 - A worldwide snapshot of technological practices

AU - Toland, Amanda Ewart

AU - Forman, Andrea

AU - Couch, Fergus J

AU - Culver, Julie O.

AU - Eccles, Diana M.

AU - Foulkes, William D.

AU - Hogervorst, Frans B.L.

AU - Houdayer, Claude

AU - Levy-Lahad, Ephrat

AU - Monteiro, Alvaro N.

AU - Neuhausen, Susan L.

AU - Plon, Sharon E.

AU - Sharan, Shyam K.

AU - Spurdle, Amanda B.

AU - Szabo, Csilla

AU - Brody, Lawrence C.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Clinical testing of BRCA1 and BRCA2 began over 20 years ago. With the expiration and overturning of the BRCA patents, limitations on which laboratories could offer commercial testing were lifted. These legal changes occurred approximately the same time as the widespread adoption of massively parallel sequencing (MPS) technologies. Little is known about how these changes impacted laboratory practices for detecting genetic alterations in hereditary breast and ovarian cancer genes. Therefore, we sought to examine current laboratory genetic testing practices for BRCA1/BRCA2. We employed an online survey of 65 questions covering four areas: laboratory characteristics, details on technological methods, variant classification, and client-support information. Eight United States (US) laboratories and 78 non-US laboratories completed the survey. Most laboratories (93%; 80/86) used MPS platforms to identify variants. Laboratories differed widely on: (1) technologies used for large rearrangement detection; (2) criteria for minimum read depths; (3) non-coding regions sequenced; (4) variant classification criteria and approaches; (5) testing volume ranging from 2 to 2.5 × 105 tests annually; and (6) deposition of variants into public databases. These data may be useful for national and international agencies to set recommendations for quality standards for BRCA1/BRCA2 clinical testing. These standards could also be applied to testing of other disease genes.

AB - Clinical testing of BRCA1 and BRCA2 began over 20 years ago. With the expiration and overturning of the BRCA patents, limitations on which laboratories could offer commercial testing were lifted. These legal changes occurred approximately the same time as the widespread adoption of massively parallel sequencing (MPS) technologies. Little is known about how these changes impacted laboratory practices for detecting genetic alterations in hereditary breast and ovarian cancer genes. Therefore, we sought to examine current laboratory genetic testing practices for BRCA1/BRCA2. We employed an online survey of 65 questions covering four areas: laboratory characteristics, details on technological methods, variant classification, and client-support information. Eight United States (US) laboratories and 78 non-US laboratories completed the survey. Most laboratories (93%; 80/86) used MPS platforms to identify variants. Laboratories differed widely on: (1) technologies used for large rearrangement detection; (2) criteria for minimum read depths; (3) non-coding regions sequenced; (4) variant classification criteria and approaches; (5) testing volume ranging from 2 to 2.5 × 105 tests annually; and (6) deposition of variants into public databases. These data may be useful for national and international agencies to set recommendations for quality standards for BRCA1/BRCA2 clinical testing. These standards could also be applied to testing of other disease genes.

UR - http://www.scopus.com/inward/record.url?scp=85042218941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042218941&partnerID=8YFLogxK

U2 - 10.1038/s41525-018-0046-7

DO - 10.1038/s41525-018-0046-7

M3 - Article

AN - SCOPUS:85042218941

VL - 3

JO - npj Genomic Medicine

JF - npj Genomic Medicine

SN - 2056-7944

IS - 1

M1 - 7

ER -